Known targets — ChEMBL curated mechanism
DHFRGARTPTGFRPTGIRPTGS1PTGS2TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8envmurAthyA
The experimentally established mechanism targets of Tromethamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 19/20 | 0.61 |
| ▸ | PPARA | Q07869 | 17/20 | 0.61 |
| ▸ | PPARD | Q03181 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5107356 | 0.93 | PPARG (0.69) | PPARGPPARAPPARD | |
| SCHEMBL14265753 | 0.93 | PPARG (0.69) | PPARGPPARAPPARD | |
| SCHEMBL5104423 | 0.88 | PPARG (0.62) | PPARGPPARAPPARD | |
| SCHEMBL5107710 | 0.87 | PPARG (0.58) | PPARGPPARAPPARD | |
| N-Benzylmethylamine SCHEMBL7525090 | 0.87 | PPARG (0.61) | PPARGPPARAPPARD | |
| SCHEMBL7526238 | 0.86 | PPARG (0.59) | PPARGPPARAPPARD | |
| SCHEMBL5107151 | 0.86 | PPARG (0.57) | PPARGPPARAPPARD | |
| SCHEMBL1868253 | 0.86 | PPARG (0.61) | PPARGPPARAPPARD | |
| SCHEMBL5107182 | 0.86 | PPARG (0.59) | PPARGPPARAPPARD | |
| SCHEMBL14265752 | 0.85 | PPARG (0.58) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020142993-A1 | Pharmaceutically acceptable salts of bicyclic compounds | DR. REDDY'S LABORATORIES LTD. | 2002-10-03 | — | — | US | claimed |
| WO-2002030914-A1 | SALTS OF BENZOTHIAZINE AND BENZOXAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2002-04-18 | — | — | WO | claimed |
| US-20020142993-A1 | Pharmaceutically acceptable salts of bicyclic compounds | DR. REDDY'S LABORATORIES LTD. | 2002-10-03 | — | — | US | disclosed |
| WO-2002030914-A1 | SALTS OF BENZOTHIAZINE AND BENZOXAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020142993-A1 | Pharmaceutically acceptable salts of bicyclic compounds | CYP3A43, ABCG2, SLC10A1 | PPARG 411/4885PPARA 1234/4885PPARD 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.